Biotech Startups

Enveda operates a drug discovery platform that reads and translates the chemistry of natural molecules to identify new medicines faster than industry averages. It serves pharmaceutical drug discovery by mapping the chemical composition of the natural world for therapeutic development.

4 investors

EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.

4 investors

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

4 investors

Erg Bio converts waste biomass into fermentable sugars and intermediates for synthetic aviation fuels and chemicals, using an advanced solvent process and a proprietary yeast that produces enzymes and ferments sugars. The technology is feedstock-agnostic and licensed from the DOE Joint BioEnergy Institute, targeting energy and chemical production markets.

4 investors

ExcepGen develops biologics, gene therapies, and vaccines using synthetic biology approaches to create therapies that operate outside normal cellular regulation constraints.

4 investors

EXCIVA is a privately held biotech company developing clinical-stage therapeutics for neuropsychiatric indications, with a focus on treating neuropsychiatric symptoms of dementia such as agitation and aggression in Alzheimer's disease. Its lead candidate, Deraphan, is in Phase 2/3 trials.

4 investors

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

4 investors

Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.

4 investors

Extracellular is a contract development and manufacturing organisation (CDMO) for animal and plant cell technologies in non-health biotech, offering R&D, regulatory support, and scale-up and contract manufacturing services. It serves innovators in cultivated meat and seafood, plant-cell-derived food ingredients, personal care and cosmetics active ingredients, and cultivated materials such as leather, cotton, and wood.

4 investors

FabricNano develops cell-free biocatalysis technology that immobilizes engineered enzymes onto scalable, environmentally friendly support materials for use in bio-processes. It offers enzyme immobilization and interaction engineering services to help companies turn biocatalysis projects into commercially viable, scalable biocatalyst products.

4 investors

Farmless uses fermentation with microbes and renewable energy to produce proteins without relying on agricultural land. It operates in the food technology and alternative protein space.

4 investors

FinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.

4 investors

Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries. The software is designed for genomics and life science researchers working with single-cell gene expression data.

4 investors

Forever Labs operates a stem cell banking service that collects, processes, and cryopreserves adult stem cells from individuals for potential use in future regenerative therapies. The company connects patients with a network of board-certified physicians across the United States and coordinates cell storage and therapeutic activation.

4 investors

Fork & Good develops cultivated meat technology using a hydroponic system approach that integrates cell biology with farming principles to produce real meat from cells at scale. The company serves food manufacturers and works toward making cultivated meat commercially viable and sustainable.

4 investors

Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases. It serves patients, healthcare providers, and biopharma companies, with tests available across all U.S. states and 45+ countries.

4 investors

Freya Biosciences is a clinical-stage immunology company developing therapies targeting inflammation and immune dysregulation in conditions affecting women, including infertility and pregnancy-related dysbiosis. It focuses on disease-modifying treatments in the underserved area of women's health.

4 investors

Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease. It provides contract research services and biomarker testing to clinical providers, pharmaceutical, biotech, and academic partners to support drug development and patient care, with operations in the US and Sub-Saharan Africa.

4 investors

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

4 investors

Geneoscopy develops innovative diagnostic technologies for gastrointestinal health, specifically focused on the detection of colorectal cancer. The company serves healthcare providers and patients seeking advanced diagnostic solutions in the medical diagnostics and cancer detection sector.

4 investors

General Proximity develops proximity-based technologies for drug discovery and development. The company employs scientists from leading academic and pharmaceutical institutions.

4 investors

Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners. Based on the investor page content, the company operates in the biotech and life sciences sector.

4 investors

4 investors

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

4 investors